Cargando…
Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
Inhibition of sodium glucose cotransporter 2 (SGLT2) has been reported as a new therapeutic strategy for treating diabetes. However, the effect of SGLT2 inhibitors on the kidney is unknown. In addition, whether SGLT2 inhibitors have an anti-inflammatory or antioxidative stress effect is still unclea...
Autores principales: | Terami, Naoto, Ogawa, Daisuke, Tachibana, Hiromi, Hatanaka, Takashi, Wada, Jun, Nakatsuka, Atsuko, Eguchi, Jun, Horiguchi, Chikage Sato, Nishii, Naoko, Yamada, Hiroshi, Takei, Kohji, Makino, Hirofumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4069074/ https://www.ncbi.nlm.nih.gov/pubmed/24960177 http://dx.doi.org/10.1371/journal.pone.0100777 |
Ejemplares similares
-
Nuclear Hormone Receptor Expression in Mouse Kidney and Renal Cell Lines
por: Ogawa, Daisuke, et al.
Publicado: (2014) -
Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose‐induced oxidative stress in type 1 diabetic mice
por: Hatanaka, Takashi, et al.
Publicado: (2016) -
Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice
por: Qiao, Panshuang, et al.
Publicado: (2022) -
Effect of the sodium–glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages
por: Takahashi, Kiyohiko, et al.
Publicado: (2018) -
Differential effects of sodium-glucose cotransporter 2 inhibitor and low-carbohydrate diet on body composition and metabolic profile in obese diabetic db/db mice
por: Kusakabe, Toru, et al.
Publicado: (2020)